Genomic/JJ
Profiling/JJ
of/IN
Liver/JJ
Cancer/NN
./.
====================
Development/NN
of/IN
liver/NN
cancers/NNS
is/VBZ
driven/VBN
largely/RB
by/IN
genomic/JJ
alterations/NNS
that/IN
deregulate/VBP
signaling/NN
pathways/NNS
,/,
influencing/VBG
growth/NN
and/CC
survival/NN
of/IN
cancer/NN
cells/NNS
./.
====================
Because/IN
of/IN
the/DT
hundreds/NNS
or/CC
thousands/NNS
of/IN
genomic/epigenomic/JJ
alterations/NNS
that/IN
have/VBP
accumulated/VBN
in/IN
the/DT
cancer/NN
genome/NN
,/,
it/PRP
is/VBZ
very/RB
challenging/JJ
to/TO
find/VB
and/CC
test/VB
candidate/NN
genes/NNS
driving/VBG
tumor/NN
development/NN
and/CC
progression/NN
./.
====================
Systematic/JJ
studies/NNS
of/IN
the/DT
liver/NN
cancer/NN
genome/NN
have/VBP
become/VBN
available/JJ
in/IN
recent/JJ
years/NNS
./.
====================
These/DT
studies/NNS
have/VBP
uncovered/JJ
new/JJ
potential/JJ
driver/RB
genes/NNS
,/,
including/VBG
those/DT
not/RB
previously/RB
known/VBN
to/TO
be/VB
involved/VBN
in/IN
the/DT
development/NN
of/IN
liver/NN
cancer/NN
./.
====================
Novel/JJ
approaches/NNS
combining/VBG
multiple/JJ
datasets/NNS
from/IN
patient/NN
tissues/NNS
have/VBP
created/VBN
an/DT
unparalleled/JJ
opportunity/NN
to/TO
uncover/JJ
potential/JJ
new/JJ
therapeutic/JJ
targets/NNS
and/CC
prognostic/predictive/JJ
biomarkers/NNS
for/IN
personalized/VBN
therapy/NN
that/IN
can/MD
improve/VB
clinical/JJ
outcomes/NNS
of/IN
the/DT
patients/NNS
with/IN
liver/NN
cancer/NN
./.
====================
Primary/JJ
liver/NN
cancer/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
common/JJ
cancers/NNS
in/IN
the/DT
world/NN
,/,
accounting/VBG
for/IN
an/DT
estimated/VBN
600,000/CD
deaths/NNS
annually/RB
[/(
1/CD
]/)
./.
====================
In/IN
Korea/NN
,/,
liver/NN
cancer/NN
is/VBZ
the/DT
second/JJ
leading/VBG
cause/VBP
of/IN
cancer-related/JJ
deaths/NNS
(/(
10,946/CD
death/NN
in/IN
2010/CD
)/)
[/(
2/CD
]/)
./.
====================
In/IN
the/DT
United/JJ
States/NNS
,/,
primary/JJ
liver/NN
cancer/NN
has/VBZ
gained/VBN
major/JJ
interest/NN
,/,
because/IN
the/DT
incidence/NN
of/IN
liver/NN
cancer/NN
has/VBZ
increased/VBN
over/IN
the/DT
past/NN
25/CD
years/NNS
,/,
and/CC
the/DT
incidence/NN
and/CC
mortality/NN
rate/NN
of/IN
liver/NN
cancer/NN
are/VBP
expected/VBN
to/TO
double/JJ
over/IN
the/DT
next/JJ
10/CD
to/TO
20/CD
years/NNS
[/(
3-5/CD
]/)
./.
====================
Therefore/RB
,/,
prevention/NN
and/CC
treatment/NN
of/IN
liver/NN
cancer/NN
are/VBP
of/IN
great/JJ
concern/NN
./.
====================
While/IN
primary/JJ
liver/NN
cancer/NN
is/VBZ
one/CD
of/IN
the/DT
few/JJ
cancers/NNS
with/IN
well-defined/JJ
major/JJ
risk/NN
factors/NNS
,/,
such/JJ
as/IN
hepatitis/NN
virus/NN
infection/NN
,/,
alcohol/NN
consumption/NN
,/,
and/CC
obesity/NN
,/,
the/DT
molecular/JJ
pathogenesis/NN
of/IN
liver/NN
cancer/NN
is/VBZ
not/RB
well/RB
understood/VBN
[/(
6-8/CD
]/)
./.
====================
Patients/NNS
with/IN
liver/NN
cancer/NN
have/VBP
a/DT
highly/RB
variable/JJ
clinical/JJ
course/NN
[/(
7/CD
,/,
9/CD
]/)
,/,
indicating/VBG
that/IN
liver/NN
cancer/NN
comprises/VBZ
several/JJ
biologically/RB
distinct/JJ
subgroups/NNS
./.
====================
Therefore/RB
,/,
it/PRP
will/MD
be/VB
necessary/JJ
to/TO
understand/VB
liver/NN
cancer/NN
at/IN
a/DT
genomic/JJ
and/CC
molecular/JJ
level/NN
for/IN
improved/JJ
stratification/NN
of/IN
patients/NNS
,/,
identification/NN
of/IN
novel/JJ
druggable/JJ
targets/NNS
,/,
and/CC
development/NN
of/IN
personalized/VBN
treatment/NN
,/,
based/VBN
on/IN
the/DT
biological/JJ
characteristics/NNS
of/IN
tumors/NNS
in/IN
each/DT
patient/NN
./.
====================
Due/IN
to/TO
the/DT
complex/NN
nature/NN
of/IN
cancers/NNS
that/IN
are/VBP
initiated/VBN
by/IN
activation/NN
of/IN
many/JJ
different/JJ
oncogenes/NNS
or/CC
inactivation/NN
of/IN
different/JJ
tumor/NN
suppressor/NN
genes/NNS
and/CC
progress/VBP
by/IN
additional/JJ
genetic/JJ
or/CC
epigenetic/JJ
alterations/NNS
,/,
conventional/JJ
gene-by-gene/NN
approaches/NNS
are/VBP
likely/JJ
to/TO
deliver/RB
only/RB
a/DT
limited/JJ
understanding/VBG
of/IN
the/DT
biological/JJ
and/CC
pathological/JJ
characteristics/NNS
of/IN
cancer/NN
cells/NNS
./.
====================
However/RB
,/,
the/DT
recent/JJ
development/NN
of/IN
technologies/NNS
for/IN
gene/NN
expression/NN
profiling/VBG
,/,
genome-wide/NN
copy/NN
number/NN
analysis/NN
,/,
and/CC
whole-genome/JJ
sequencing/NN
has/VBZ
enabled/VBN
the/DT
comprehensive/JJ
characterization/NN
of/IN
entire/JJ
cancer/NN
genomes/NNS
./.
====================
This/DT
information/NN
promises/VBZ
to/TO
improve/VB
our/PRP$
understanding/NN
of/IN
the/DT
genetic/JJ
and/CC
epigenetic/JJ
alterations/NNS
driving/VBG
the/DT
development/NN
of/IN
liver/NN
cancer/NN
,/,
as/IN
well/RB
as/IN
ultimately/RB
provide/VBP
guidance/NN
on/IN
personalized/VBN
treatment/NN
of/IN
patients/NNS
./.
====================
Although/IN
these/DT
large-scale/JJ
genomic/JJ
data/NNS
promise/VBP
improvement/JJ
in/IN
the/DT
treatment/NN
of/IN
liver/NN
cancer/NN
,/,
challenges/NNS
remain/VBP
for/IN
the/DT
management/JJ
and/CC
integration/NN
of/IN
these/DT
data/NNS
for/IN
a/DT
better/RBR
understanding/NN
of/IN
how/WRB
these/DT
alterations/NNS
give/VBP
rise/NN
to/TO
the/DT
development/NN
of/IN
liver/NN
cancer/NN
and/CC
,/,
most/JJS
importantly/RB
,/,
the/DT
translation/NN
of/IN
these/DT
findings/NNS
into/IN
personalized/VBN
patient/NN
treatment/NN
./.
====================
Comparative/JJ
genomic/JJ
hybridization/NN
(/(
CGH/NN
)/)
====================
Since/IN
the/DT
discovery/NN
of/IN
frequent/JJ
genetic/JJ
rearrangements/NNS
and/CC
copy/NN
number/NN
aberrations/NNS
in/IN
the/DT
cancer/NN
genome/NN
[/(
10/CD
]/)
,/,
cytogenetic/JJ
methods/NNS
have/VBP
been/VBN
used/VBN
widely/RB
to/TO
find/VB
the/DT
genetic/JJ
changes/NNS
in/IN
cancer/NN
genomes/NNS
./.
====================
The/DT
CGH/NN
method/NN
was/VBD
the/DT
first/JJ
tool/NN
to/TO
provide/VB
a/DT
genome-wide/NN
investigation/NN
of/IN
copy-number/NN
alterations/NNS
in/IN
cancer/NN
[/(
11/CD
]/)
./.
====================
Increased/VBN
or/CC
decreased/VBD
regions/NNS
of/IN
copy/NN
number/NN
are/VBP
believed/VBN
to/TO
have/VB
either/CC
oncogenes/NNS
or/CC
tumor/NN
suppressor/NN
genes/NNS
./.
====================
Although/IN
the/DT
resolution/NN
of/IN
early/JJ
CGH/NN
mapping/VBG
technology/NN
is/VBZ
limited/JJ
by/IN
2/CD
Mbp/JJ
(/(
high-copy-number/JJR
amplifications/NNS
)/)
to/TO
10/CD
Mbp/JJ
(/(
low-copy-number/JJR
amplification/NN
or/CC
deletion/NN
)/)
,/,
this/DT
method/NN
has/VBZ
identified/VBN
many/JJ
loci/NNS
for/IN
oncogenes/NNS
and/CC
tumor/NN
suppressor/NN
genes/NNS
in/IN
liver/NN
cancer/NN
./.
====================
Multiple/JJ
studies/NNS
have/VBP
reported/VBN
amplification/NN
of/IN
the/DT
8q24/NN
loci/NNS
,/,
in/IN
which/WDT
MYC/NN
is/VBZ
located/JJ
[/(
12-15/CD
]/)
./.
====================
Other/JJ
studies/NNS
also/RB
identified/VBD
prevalent/JJ
amplification/NN
of/IN
the/DT
1q/NN
,/,
6p/JJ
,/,
and/CC
17q/NN
regions/NNS
and/CC
frequent/JJ
deletion/NN
of/IN
the/DT
8p/JJ
,/,
16q/NN
,/,
4q/NNP
,/,
and/CC
17p/NN
regions/NNS
[/(
12/CD
,/,
15/CD
]/)
./.
====================
Microarray-based/VBN
technologies/NNS
====================
Microarray/NN
technology/NN
has/VBZ
been/VBN
used/VBN
extensively/RB
to/TO
gather/VB
global-scale/JJ
data/NNS
from/IN
cell/NN
lines/NNS
or/CC
tissues/NNS
of/IN
interest/NN
./.
====================
This/DT
technology/NN
was/VBD
first/JJ
used/VBN
to/TO
make/VB
a/DT
quantitative/JJ
assessment/NN
of/IN
mRNAs/NNS
or/CC
non-coding/JJ
RNAs/NNS
./.
====================
Gene/NN
expression/NN
profiling/VBG
studies/NNS
based/VBN
on/IN
microarray/NN
technologies/NNS
have/VBP
identified/VBN
conserved/VBN
gene/NN
expression/NN
signatures/NNS
that/DT
are/VBP
significantly/RB
related/JJ
with/IN
clinical/JJ
outcomes/NNS
or/CC
pathological/JJ
phenotypes/NNS
and/CC
have/VBP
uncovered/JJ
many/JJ
subgroups/NNS
of/IN
cancer/NN
that/IN
were/VBD
not/RB
recognized/VBN
with/IN
conventional/JJ
approaches/NNS
in/IN
a/DT
variety/NN
of/IN
cancers/NNS
[/(
16-18/CD
]/)
./.
====================
These/DT
approaches/NNS
have/VBP
been/VBN
used/VBN
successfully/RB
to/TO
identify/VB
therapeutic/JJ
targets/NNS
for/IN
various/JJ
cancers/NNS
and/CC
to/TO
predict/VB
overall/JJ
survival/NN
or/CC
recurrence-free/JJ
survival/NN
rates/NNS
of/IN
cancer/NN
patients/NNS
[/(
19-21/CD
]/)
./.
====================
Use/NN
of/IN
microarray/NN
technology/NN
is/VBZ
not/RB
restricted/JJ
to/TO
genome-wide/VB
gene/NN
expression/NN
profiling/VBG
of/IN
cells/NNS
or/CC
tissues/NNS
but/CC
expands/VBZ
to/TO
uncovering/VBG
single-nucleotide/JJ
polymorphisms/NNS
associated/VBN
with/IN
cancer/NN
risk/NN
,/,
methylation/NN
status/NN
of/IN
gene/NN
promoters/NNS
,/,
DNA/NN
copy/NN
number/NN
alterations/NNS
,/,
protein/NN
expression/NN
profiling/VBG
,/,
and/CC
re-sequencing/VBG
of/IN
cancer/NN
genomes/NNS
./.
====================
Because/IN
microarray-based/VBN
CGH/NN
can/MD
provide/VB
copy-number/NN
analyses/NNS
with/IN
much/RB
higher/JJR
resolution/NN
than/IN
conventional/JJ
CGH/NN
,/,
it/PRP
has/VBZ
quickly/RB
replaced/VBN
conventional/JJ
CGH/NN
[/(
22/CD
,/,
23/CD
]/)
./.
====================
Microarray/NN
technologies/NNS
were/VBD
also/RB
adopted/VBN
by/IN
the/DT
proteomics/NNS
community/NN
./.
====================
Protein/NN
microarray/NN
was/VBD
quickly/RB
established/VBN
by/IN
rapid/JJ
improvements/NNS
to/TO
miniaturizing/JJ
western/NN
blotting/NN
and/CC
tissue/NN
lysate/NN
dotting/VBG
technologies/NNS
onto/IN
solid/JJ
surfaces/NNS
./.
====================
There/EX
are/VBP
two/CD
different/JJ
experimental/JJ
approaches/NNS
for/IN
protein/NN
arrays/NNS
:/:
forward-phase/JJ
protein/NN
array/NN
(/(
FPPA/NN
)/)
and/CC
reverse-phase/VBP
protein/NN
array/NN
(/(
RPPA/NN
)/)
./.
====================
In/IN
FPPA/NN
,/,
antibodies/NNS
or/CC
polypeptides/NNS
are/VBP
printed/VBN
on/IN
the/DT
slide/JJ
surface/NN
,/,
and/CC
each/DT
slide/JJ
?/.
is/VBZ
incubated/VBN
with/IN
labeled/VBN
tissue/NN
or/CC
cell/NN
lysate/NN
./.
====================
This/DT
approach/NN
allows/VBZ
one/CD
to/TO
simultaneously/RB
measure/VB
multiple/JJ
protein/NN
features/NNS
,/,
such/JJ
as/IN
expression/NN
,/,
interaction/NN
with/IN
peptide/NN
ligands/NNS
,/,
and/CC
protein/NN
phosphorylation/NN
,/,
from/IN
the/DT
samples/NNS
./.
====================
In/IN
RPPA/NN
,/,
an/DT
individual/JJ
tissue/NN
lysate/NN
in/IN
printed/JJ
on/IN
the/DT
slide/JJ
surface/NN
,/,
and/CC
each/DT
RPPA/NN
slide/JJ
consists/VBZ
of/IN
hundreds/VBZ
or/CC
thousands/NNS
of/IN
tissue/NN
samples/NNS
./.
====================
Each/DT
slide/JJ
is/VBZ
then/RB
probed/VBN
with/IN
one/CD
peptide/NN
ligand/NN
or/CC
antibody/NN
at/IN
a/DT
time/NN
,/,
and/CC
a/DT
protein/NN
feature/NN
of/IN
interest/NN
is/VBZ
assessed/VBN
and/CC
compared/VBD
across/IN
many/JJ
tissues/NNS
or/CC
cell/NN
lines/NNS
./.
====================
Because/IN
RPPA/NN
needs/VBZ
only/RB
several/JJ
thousands/NNS
of/IN
cells/NNS
to/TO
collect/VB
high-quality/JJ
data/NNS
,/,
it/PRP
is/VBZ
better/RBR
suited/JJ
for/IN
cancer/NN
research/NN
./.
====================
In/IN
contrast/NN
,/,
FPPA/NN
is/VBZ
not/RB
suitable/JJ
for/IN
tissue-based/JJ
studies/NNS
,/,
because/IN
it/PRP
needs/VBZ
a/DT
large/JJ
quantity/NN
of/IN
tissue/NN
or/CC
cell/NN
lysate/NN
for/IN
detection/NN
[/(
24-27/NN
]/)
./.
====================
Next-generation/NN
sequencing/NN
====================
Due/IN
to/TO
the/DT
emergence/NN
of/IN
second-generation/NN
sequencing/NN
technologies/NNS
that/DT
allow/VBP
massive/JJ
parallel/NN
collection/NN
of/IN
sequence/NN
information/NN
,/,
the/DT
cost/JJ
per/IN
base/NN
for/IN
sequencing/NN
the/DT
entire/JJ
genome/NN
has/VBZ
reduced/VBN
dramatically/RB
[/(
28/CD
]/)
./.
====================
These/DT
new/JJ
technologies/NNS
provided/VBD
unique/JJ
opportunities/NNS
to/TO
investigate/VB
all/DT
sequences/NNS
of/IN
entire/JJ
cancer/NN
genomes/NNS
to/TO
uncover/VB
the/DT
genetic/JJ
changes/NNS
that/WDT
arise/VBP
during/IN
cancer/NN
development/NN
./.
====================
Many/JJ
different/JJ
technologies/NNS
have/VBP
been/VBN
developed/VBN
by/IN
different/JJ
companies/NNS
:/:
Roche/DT
Applied/VBN
Science/NNP
(/(
454/CD
Genome/NNP
Sequencer/NN
FLX/NN
System/NN
;/:
Indianapolis/RB
,/,
IN/NNP
,/,
USA/NNP
)/)
,/,
Life/NNP
Technologies/NNS
(/(
Sequencing/NN
by/IN
Oligonucleotide/NN
Ligation/NN
and/CC
Detection/NN
or/CC
SOLiD/JJ
;/:
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
Illumina/NNP
(/(
Genome/NNP
Analyzer/DT
II/CD
;/:
San/NNP
Diego/RB
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
Helicos/RB
BioSciences/NNS
(/(
HeliScope/JJ
Single/JJ
Molecule/NNP
Sequencer/NN
;/:
Cambridge/NNP
,/,
MA/NNP
,/,
USA/NNP
)/)
,/,
and/CC
Ion/JJ
Torrent/JJ
Systems/NNS
(/(
now/RB
owned/JJ
by/IN
Life/JJ
Technologies/NNS
,/,
Ion/NNP
Proton/JJ
System/NN
)/)
./.
====================
These/DT
new/JJ
technologies/NNS
have/VBP
been/VBN
used/VBN
to/TO
identify/VB
potential/JJ
driver/RB
mutations/NNS
in/IN
the/DT
development/NN
of/IN
liver/NN
cancer/NN
through/IN
whole-genome/JJ
and/CC
-exome/JJ
sequencing/NN
./.
====================
The/DT
first/JJ
sequencing/NN
of/IN
the/DT
primary/JJ
liver/NN
cancer/NN
genome/NN
revealed/VBD
a/DT
total/JJ
of/IN
11,731/CD
somatic/JJ
mutations/NNS
[/(
29/CD
]/)
./.
====================
Following/VBG
studies/NNS
showed/VBD
that/IN
the/DT
CTNNB1/NN
,/,
TP53/NN
,/,
and/CC
EGFR/NN
genes/NNS
were/VBD
frequently/RB
mutated/VBN
in/IN
liver/NN
cancer/NN
[/(
30-33/CD
]/)
./.
====================
Additionally/RB
,/,
the/DT
ARID/NN
family/NN
,/,
including/VBG
ARID1A/NN
,/,
ARID1B/NN
,/,
and/CC
ARID2/NN
,/,
was/VBD
mutated/VBN
in/IN
about/RB
half/RB
of/IN
all/DT
tumors/NNS
,/,
suggesting/VBG
a/DT
potential/JJ
role/NN
of/IN
them/PRP
in/IN
the/DT
development/NN
of/IN
liver/NN
cancer/NN
./.
====================
In/IN
previous/JJ
studies/NNS
[/(
18/CD
,/,
34-37/CD
]/)
,/,
gene/NN
expression/NN
data/NNS
from/IN
human/JJ
liver/NN
cancer/NN
have/VBP
identified/VBN
several/JJ
subgroups/NNS
that/IN
are/VBP
significantly/RB
associated/VBN
with/IN
clinical/JJ
outcomes/NNS
,/,
such/JJ
as/IN
overall/JJ
survival/NN
and/CC
recurrence-free/JJ
survival/NN
./.
====================
These/DT
findings/NNS
strongly/RB
indicated/VBD
that/IN
gene/NN
expression/NN
patterns/NNS
faithfully/RB
reflect/VBP
biological/JJ
and/CC
pathological/JJ
heterogeneity/NN
among/IN
patients/NNS
with/IN
liver/NN
cancer/NN
and/CC
would/MD
be/VB
highly/RB
valuable/JJ
in/IN
predicting/VBG
the/DT
clinical/JJ
outcome/NN
of/IN
patients/NNS
./.
====================
The/DT
current/JJ
challenge/NN
for/IN
clinical/JJ
use/NN
is/VBZ
to/TO
identify/VB
those/DT
who/WP
will/MD
not/RB
benefit/VB
from/IN
conventional/JJ
treatments/NNS
and/CC
to/TO
offer/VB
alternative/JJ
therapies/NNS
./.
====================
If/IN
master/JJ
drivers/VBZ
,/,
such/JJ
as/IN
genes/NNS
or/CC
pathways/NNS
determining/VBG
the/DT
biological/JJ
characteristics/NNS
of/IN
the/DT
tumors/NNS
,/,
can/MD
be/VB
identified/VBN
,/,
we/PRP
can/MD
explore/VB
their/PRP$
therapeutic/JJ
potentials/NNS
./.
====================
However/RB
,/,
gene/NN
expression/NN
profiling/VBG
approaches/NNS
are/VBP
also/RB
limited/JJ
,/,
because/IN
they/PRP
only/RB
provide/VBP
information/NN
related/JJ
to/TO
transcriptional/JJ
regulation/NN
./.
====================
Integromics/NNS
:/:
Integration/NN
of/IN
multiple-omics/NNS
data/NNS
====================
Previous/JJ
studies/NNS
undoubtedly/RB
showed/VBD
that/IN
gene/NN
expression/NN
patterns/NNS
(/(
or/CC
signatures/NNS
)/)
are/VBP
useful/JJ
markers/NNS
that/WDT
can/MD
stratify/VB
patients/NNS
and/CC
offer/VBP
useful/JJ
prognostic/JJ
information/NN
[/(
18/CD
,/,
37-42/CD
]/)
./.
====================
The/DT
current/JJ
research/NN
focus/IN
has/VBZ
moved/VBN
to/TO
uncovering/VBG
genetic/epigenetic/JJ
factors/NNS
that/WDT
are/VBP
key/JJ
regulators/NNS
of/IN
specific/JJ
signaling/NN
pathways/NNS
altered/JJ
in/IN
malignant/JJ
cancer/NN
cells/NNS
,/,
potentially/RB
guiding/VBG
the/DT
discovery/NN
of/IN
new/JJ
therapeutic/JJ
(/(
and/CC
druggable/JJ
)/)
targets/VBZ
[/(
8/CD
,/,
43-45/CD
]/)
./.
====================
But/CC
,/,
the/DT
selection/NN
of/IN
such/JJ
candidates/NNS
for/IN
future/JJ
validations/NNS
from/IN
long/JJ
gene/NN
lists/NNS
produced/VBN
by/IN
genome-wide/NN
screening/NN
is/VBZ
a/DT
significant/JJ
challenge/NN
because/IN
of/IN
potential/JJ
confounding/VBG
factors/NNS
embedded/JJ
in/IN
many/JJ
genome-wide/NN
data/NNS
from/IN
human/JJ
cancers/NNS
./.
====================
Furthermore/RB
,/,
because/IN
the/DT
gene/NN
expression/NN
data/NNS
from/IN
tumor/NN
tissues/NNS
only/RB
provide/VBP
``/JJ
snapshot/RB
''/NNP
information/NN
of/IN
genetic/epigenetic/JJ
alterations/NNS
and/CC
lack/VBP
in-depth/IN
information/NN
on/IN
interactive/JJ
and/CC
time-dependent/JJ
alterations/NNS
during/IN
tumor/NN
progression/NN
,/,
it/PRP
is/VBZ
not/RB
easy/RB
to/TO
distinguish/VB
the/DT
driver/RB
genes/NNS
from/IN
passenger/NN
genes/NNS
whose/WP$
alterations/NNS
simply/RB
echo/DT
changes/NNS
in/IN
cell/NN
proliferation/NN
or/CC
organ/NN
physiology/NN
./.
====================
As/IN
discussed/VBN
earlier/RBR
,/,
CGH/NN
analyses/NNS
have/VBP
identified/VBN
many/JJ
recurrent/JJ
candidate/NN
loci/NNS
of/IN
DNA/NN
copy/NN
number/NN
changes/NNS
in/IN
liver/NN
cancer/NN
./.
====================
Some/DT
of/IN
these/DT
genomic/JJ
regions/NNS
have/VBP
well-recognized/VBN
tumor/NN
suppressor/NN
genes/NNS
and/CC
oncogenes/NNS
./.
====================
However/RB
,/,
because/IN
of/IN
the/DT
large/JJ
number/NN
of/IN
candidate/NN
genes/NNS
in/IN
the/DT
identified/VBN
genomic/JJ
loci/NNS
,/,
functional/JJ
validation/NN
of/IN
all/DT
candidates/NNS
would/MD
be/VB
impractical/JJ
./.
====================
Thus/RB
,/,
there/EX
is/VBZ
an/DT
urgent/JJ
demand/CC
for/IN
development/NN
of/IN
a/DT
new/JJ
approach/NN
that/DT
would/MD
quickly/RB
prioritize/VBP
candidates/NNS
according/VBG
to/TO
the/DT
likelihood/JJ
of/IN
their/PRP$
direct/JJ
involvement/NN
in/IN
tumor/NN
development/NN
./.
====================
In/IN
a/DT
previous/JJ
study/NN
,/,
systematic/JJ
integration/NN
of/IN
gene/NN
copy/NN
number/NN
data/NNS
and/CC
gene/NN
expression/NN
from/IN
the/DT
same/JJ
patients/NNS
has/VBZ
been/VBN
proposed/VBN
to/TO
identify/VB
potential/JJ
driver/RB
genes/NNS
[/(
46/CD
]/)
./.
====================
This/DT
study/NN
demonstrated/VBD
that/IN
DNA/NN
copy/NN
number/NN
alteration/NN
data/NNS
provide/VBP
additional/JJ
prognostic/JJ
significance/NN
./.
====================
Integrative/JJ
analysis/NN
of/IN
copy/NN
number/NN
alteration/NN
data/NNS
and/CC
gene/NN
expression/NN
further/RBR
identified/VBN
50/CD
driver/RB
candidates/NNS
whose/WP$
activation/NN
was/VBD
triggered/VBN
by/IN
copy/NN
number/NN
amplifications/NNS
of/IN
genes/NNS
and/CC
also/RB
significantly/RB
associated/VBN
with/IN
aggressive/JJ
tumor/NN
phenotypes/NNS
in/IN
liver/NN
cancer/NN
./.
====================
Alterations/NNS
in/IN
DNA/NN
copy/NN
number/NN
and/CC
expression/NN
patterns/NNS
of/IN
thousands/NNS
of/IN
genes/NNS
are/VBP
important/JJ
characteristics/NNS
of/IN
many/JJ
cancer/NN
cells/NNS
./.
====================
Because/IN
the/DT
use/NN
of/IN
high-throughput/JJ
microarray-based/VBN
technologies/NNS
,/,
mass/NN
spectrometry/NN
,/,
and/CC
second-generation/NN
sequencers/NNS
for/IN
the/DT
analysis/NN
of/IN
cancer/NN
genomes/NNS
inevitably/RB
produces/VBZ
many/JJ
false-positive/JJ
results/NNS
,/,
it/PRP
is/VBZ
not/RB
easy/RB
to/TO
select/JJ
practical/JJ
numbers/NNS
of/IN
candidate/NN
genes/NNS
for/IN
future/JJ
evaluation/NN
of/IN
them/PRP
as/IN
therapeutic/JJ
targets/NNS
and/or/CC
prognostic/predictive/JJ
biomarkers/NNS
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
important/JJ
to/TO
combine/VB
two/CD
or/CC
more/RBR
genomic/JJ
scale/NN
datasets/NNS
(/(
e.g./FW
,/,
array-based/VBN
CGH/NN
data/NNS
,/,
promoter/NN
methylation/NN
,/,
and/CC
expression/NN
of/IN
coding/VBG
or/CC
non-coding/JJ
genes/NNS
)/)
,/,
collected/JJ
independently/RB
from/IN
the/DT
same/JJ
tissues/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
RPPA/NN
is/VBZ
a/DT
newly/RB
established/VBN
proteomic/JJ
technology/NN
[/(
24-27/NN
]/)
that/IN
provides/VBZ
quantitative/JJ
assessment/NN
of/IN
the/DT
expression/NN
and/CC
modification/NN
of/IN
many/JJ
proteins/NNS
./.
====================
For/IN
example/NN
,/,
the/DT
phosphorylation/NN
level/NN
of/IN
particular/JJ
proteins/NNS
can/MD
be/VB
estimated/VBN
easily/RB
by/IN
using/VBG
antibodies/NNS
specific/JJ
to/TO
certain/JJ
phosphorylation/NN
sites/NNS
of/IN
proteins/NNS
./.
====================
Use/NN
of/IN
the/DT
phosphorylation/NN
antibodies/NNS
allows/VBZ
us/PRP
to/TO
assess/VB
the/DT
signaling/NN
pathways/NNS
by/IN
looking/VBG
at/IN
many/JJ
kinase/NN
substrates/NNS
simultaneously/RB
through/IN
multiplexed/JJ
phosphorylation-specific/JJ
antibody/NN
analysis/NN
./.
====================
However/RB
,/,
assessment/NN
of/IN
signaling/NN
pathways/NNS
by/IN
RPPA/NN
is/VBZ
restricted/JJ
by/IN
the/DT
availability/NN
of/IN
antibodies/NNS
with/IN
very/RB
high/JJ
specificity/NN
./.
====================
This/DT
limitation/NN
can/MD
be/VB
overcome/VBN
by/IN
integration/NN
of/IN
multiple/JJ
datasets/NNS
for/IN
systematic/JJ
analysis/NN
./.
====================
Integration/NN
of/IN
proteomic/JJ
data/NNS
with/IN
genomic/JJ
data/NNS
would/MD
significantly/RB
help/VB
us/PRP
have/VBP
better/RBR
insights/NNS
into/IN
tumor/NN
development/NN
and/CC
progression/NN
./.
====================
Furthermore/RB
,/,
contributor/NN
genes/NNS
(/(
or/CC
drivers/VBZ
)/)
will/MD
be/VB
quickly/RB
identified/VBN
by/IN
integration/NN
of/IN
proteomic/JJ
data/NNS
with/IN
one/CD
or/CC
more/RBR
genomic/JJ
datasets/NNS
./.
====================
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
(/(
TCGA/NN
)/)
Project/NN
:/:
new/JJ
opportunity/NN
for/IN
cancer/NN
genomics/NNS
====================
TCGA/DT
is/VBZ
a/DT
landmark/NN
research/NN
program/NN
supported/VBD
by/IN
the/DT
National/JJ
Human/JJ
Genome/NN
Research/NN
Institute/JJ
and/CC
National/JJ
Cancer/NN
Institute/JJ
at/IN
the/DT
National/JJ
Institutes/NNS
of/IN
Health/NN
in/IN
the/DT
United/JJ
States/NNS
that/DT
was/VBD
started/VBN
as/IN
a/DT
pilot/JJ
project/VB
in/IN
2006/CD
and/CC
expanded/VBN
later/RB
in/IN
2009/CD
./.
====================
The/DT
goal/NN
of/IN
TCGA/NN
is/VBZ
to/TO
collect/VB
comprehensive/JJ
genomic/JJ
and/CC
proteomic/JJ
information/NN
on/IN
all/DT
major/JJ
human/JJ
cancers/NNS
,/,
including/VBG
liver/NN
cancer/NN
./.
====================
Initial/JJ
efforts/NNS
focused/VBN
on/IN
glioblastoma/NN
,/,
lung/NN
squamous/JJ
cell/NN
cancer/NN
,/,
and/CC
ovarian/JJ
cancer/NN
as/IN
pilot/NN
projects/NNS
[/(
47-50/CD
]/)
./.
====================
By/IN
using/VBG
various/JJ
different/JJ
platforms/NNS
,/,
TCGA/NN
currently/RB
gathers/NNS
many/JJ
different/JJ
genome-wide/NN
data/NNS
,/,
including/VBG
mRNA/NN
expression/NN
,/,
microRNA/NN
expression/NN
,/,
somatic/JJ
mutations/NNS
,/,
copy/NN
number/NN
alterations/NNS
,/,
and/CC
promoter/NN
methylation/NN
./.
====================
In/IN
addition/NN
,/,
it/PRP
also/RB
generates/VBZ
proteomic/JJ
data/NNS
by/IN
using/VBG
RPPA/NN
technology/NN
./.
====================
The/DT
project/JJ
plans/NNS
to/TO
collect/VB
genomic/JJ
and/CC
proteomic/JJ
data/NNS
from/IN
more/RBR
than/IN
500/CD
tissues/NNS
per/IN
cancer/NN
type/NN
and/CC
release/NN
the/DT
data/NNS
to/TO
the/DT
public/JJ
without/IN
any/DT
restriction/NN
in/IN
use/NN
of/IN
the/DT
data/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
This/DT
ambitious/JJ
project/VB
has/VBZ
identified/VBN
novel/JJ
driver/RB
genes/NNS
and/CC
biomarkers/NNS
on/IN
the/DT
basis/NN
of/IN
genomic/JJ
,/,
transcriptomic/JJ
,/,
proteomic/JJ
,/,
and/CC
epigenomic/JJ
alterations/NNS
./.
====================
Some/DT
findings/NNS
are/VBP
clinically/RB
relevant/JJ
and/CC
unexpected/JJ
./.
====================
For/IN
example/NN
,/,
we/PRP
have/VBP
now/RB
learned/VBN
that/DT
non-hypermutated/JJ
adenocarcinomas/NNS
of/IN
the/DT
colon/NN
and/CC
rectum/NN
are/VBP
not/RB
distinguishable/JJ
at/IN
the/DT
genomic/JJ
level/NN
[/(
51/CD
]/)
./.
====================
In/IN
lung/NN
squamous/JJ
cell/NN
cancer/NN
,/,
while/IN
KRAS/NN
and/CC
EGFR/NN
mutations/NNS
,/,
the/DT
most/JJS
commonly/RB
activated/VBN
oncogenes/NNS
in/IN
lung/NN
adenocarcinoma/NN
,/,
are/VBP
extremely/RB
rare/JJ
,/,
alterations/NNS
in/IN
the/DT
FGFR/NN
kinase/NN
family/NN
are/VBP
common/JJ
[/(
49/CD
]/)
./.
====================
Thus/RB
,/,
massive/JJ
data/NNS
from/IN
a/DT
large/JJ
number/NN
of/IN
tissues/NNS
have/VBP
created/VBN
an/DT
unprecedented/JJ
opportunity/NN
for/IN
taking/VBG
an/DT
integrated/JJ
approach/NN
toward/IN
a/DT
systems-level/JJ
understanding/VBG
of/IN
disruptions/NNS
in/IN
cellular/JJ
and/CC
molecular/JJ
pathways/NNS
in/IN
cancer/NN
./.
====================
Genomics/NNS
has/VBZ
become/VBN
a/DT
dominant/JJ
tool/NN
for/IN
understanding/VBG
cancer/NN
biology/NN
,/,
revealing/VBG
unexpected/JJ
surprises/NNS
and/CC
providing/VBG
cancer/NN
classification/NN
according/VBG
to/TO
biological/JJ
differences/NNS
./.
====================
The/DT
amount/NN
of/IN
liver/NN
cancer-related/VBD
genomic/JJ
data/NNS
that/WDT
have/VBP
generated/VBN
during/IN
the/DT
past/NN
few/JJ
years/NNS
is/VBZ
really/RB
incredible/JJ
./.
====================
Analysis/NN
approaches/NNS
of/IN
these/DT
data/NNS
have/VBP
been/VBN
advanced/JJ
to/TO
efficiently/RB
process/NN
this/DT
information/NN
and/CC
allow/VBP
us/PRP
to/TO
perform/VB
integrated/VBN
genome-wide/NN
analysis/NN
on/IN
a/DT
scale/JJ
previously/RB
unthinkable/JJ
./.
====================
These/DT
approaches/NNS
are/VBP
also/RB
beginning/VBG
to/TO
investigate/VB
the/DT
dense/JJ
network/NN
of/IN
molecular/JJ
pathways/NNS
driving/VBG
the/DT
development/NN
of/IN
liver/NN
cancer/NN
./.
====================
The/DT
anticipated/JJ
benefits/VBZ
of/IN
these/DT
data/NNS
will/MD
be/VB
more/RBR
a/DT
faithful/JJ
assessment/NN
of/IN
prognosis/NN
than/IN
the/DT
current/JJ
stage/NN
system/NN
,/,
improved/VBD
prediction/NN
of/IN
treatment/NN
response/NN
,/,
and/CC
discovery/NN
of/IN
new/JJ
therapeutic/JJ
targets/NNS
./.
====================
Future/JJ
challenges/NNS
lie/VBP
in/IN
translating/VBG
this/DT
discovery/NN
into/IN
personalized/VBN
treatment/NN
for/IN
the/DT
patient/NN
with/IN
liver/NN
cancer/NN
./.
====================
Integromics/NNS
approaches/NNS
./.
====================
Genomics/NNS
data/NNS
provide/VBP
long/JJ
lists/NNS
of/IN
candidate/NN
driver/RB
genes/NNS
or/CC
proteins/NNS
./.
====================
Integration/NN
of/IN
these/DT
independently/RB
generated/VBN
data/NNS
from/IN
the/DT
same/JJ
specimens/NNS
will/MD
greatly/RB
improve/VBP
the/DT
chance/NN
of/IN
identifying/VBG
real/JJ
driver/RB
genes/NNS
or/CC
therapeutic/JJ
targets/NNS
./.
====================
Cancer/NN
types/NNS
investigated/VBD
by/IN
the/DT
TCGA/NN
project/NN
====================
